Our Latest News - BUHLMANN

BUHLMANN News

Usability of a Home-Based Test for the Measurement of Fecal Calprotectin in Asymptomatic IBD Patients Digestive and Liver Disease

IBDoc® Citation: Bello C, Roseth A, Guardiola J, Reenaers C, Ruiz-Cerulla A, Kemseke C Van, Arajol C, Reinhard C, Seidel L, Louis E.Usability of a home-based test for the measurement of fecal calprotectin in asymptomatic IBD patients. Digestive and Liver Disease. 2017 May 19. pii: S1590-8658(17)30886-1. http://dx.doi.org/10.1016/j.dld.2017.05.009 PMID: 28587751 Highlights from this Publication “ …Globally, the correlation between
Continue Reading

BUHLMANN LabSense News: Spring 2017 Edition

BUHLMANN Diagnostics Corp is proud to release the third edition of our newsletter. View the latest information, new happenings, products highlights, citations, and promotions in the BUHLMANN LabSense News.  Here you will also be able to access valuable resources, applications, and other newsworthy items specific to fields of in vitro diagnostics and scientific research. In this edition,
Continue Reading

Correlation of Rapid Point-of-Care vs Send-Out Fecal Calprotectin Monitoring in Pediatric Inflammatory Bowel Disease

BÜHLMANN Quantum Blue® fCAL extended Citation: Rodriguez, A. et al.  Correlation of rapid point-of-care vs send-out fecal calprotectin monitoring in pediatric inflammatory bowel disease. World J Gastrointest Pharmacol Ther 8(2):127-130. Published online May 6, 2017. doi: 10.4292/wjgpt.v8.i2.127. Highlight from this Publication “In summary, we present the first correlation study of rapid POC calprotectin testing in a pediatric IBD
Continue Reading

Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide

BÜHLMANN fCAL® ELISA: Heidi A, Park KT, Rheenen PF. Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide. Inflamm Bowel Dis. 2017 Jun;23(6):894-902. doi: 10.1097/MIB.0000000000001082. PMID: 28511198 Highlights from this Publication “This systematic review shows that the relapsing remitting nature of IBD becomes less unpredictable
Continue Reading

Visit BUHLMANN at DDW 2017- Booth 1925

Digestive Diseases Week (DDW) 2017 BUHLMANN Diagnostics Corp  Booth: #1925 May 06 - 09, 2017 | McCormick Place | Chicago, IL Learn More Click & Contact DDW 2017 BUHLMANN Team Connect with our team ahead of time, learn more about our Calprotectin Assays or schedule a meeting! Collin Shaw, VP of Business Development Jennifer Stuart, Technical
Continue Reading

BUHLMANN Highlights: GanglioCombi MAG ELISA

BÜHLMANN GanglioCombi® MAG ELISA is for Research Use Only. Not for use in diagnostic procedures. Health Canada Licence: 100476 DOWNLOAD WHITE PAPER BÜHLMANN GanglioCombi® MAG ELISA Comprehensive assay for anti-MAG and most prevalent anti-Ganglioside antibodies: (GM1, GM2, GD1a, GD1b, and GQ1b). The Neuroimmunology product line by BÜHLMANN is a list of robust assays for simple, esoteric
Continue Reading

The Value of Calprotectin in Inflammatory Bowel Disease Management

Calprotectin: The Key to a Successful Treatment Pathway for IBD What is Inflammatory Bowel Disease? Inflammatory Bowel Disease (IBD) is a chronic inflammatory disease of the gut, which presents with periods of inflammatory activity (flares) and quiescent phases (remission) as  can be seen in many chronic diseases. IBD includes several different diseases; the two most
Continue Reading

Validation of a Care Pathway for the Use of Faecal Calprotectin in Monitoring Patients with Crohn’s Disease

BÜHLMANN fCAL® ELISA Citation: Turvill J, Rook L, Rawle M, et al. Validation of a care pathway for the use of faecal calprotectin in monitoring patients with Crohn's disease. Frontline Gastroenterology Published Online First: 30 January 2017. doi: 10.1136/flgastro-2016-100780. Highlights from this Publication “In patients with Crohn’s Disease, established on therapy, fecal calprotectin effectively identifies those who
Continue Reading

Connect with BUHLMANN Diagnostics Corp at CDDW 2017

Canadian Digestive Diseases Week (CDDW) 2017 BUHLMANN Diagnostics Corp Booth: #1032 Mar 03 – 06, 2017 LOCATION The Fairmont Banff Springs Banff, Alberta LEARN MORE Click & Contact CDDW 2017 BUHLMANN Team Connect with our team ahead of time, learn more about our Calprotectin Assays or schedule a meeting! COLLIN SHAW VP of Business Development
Continue Reading

Higher sensitivity detecting anti-myelin-associatedglycoprotein (MAG) IgM autoantibody using antigen purified from human brain

BÜHLMANN Anti-MAG Autoantibodies ELISA: Jaskowski et al. Higher sensitivity detecting anti-myelin-associatedglycoprotein (MAG) IgM autoantibody using antigen purified from human brain. 8th International Congress of Neuroimmunology. October 15-19, 2006.  Nagoya, Japan. Highlights from this Publication "The MAG EIA showed excellent sensitivity (97.5%) when compared to Western blot and has the advantages of being objective...and identifying [subjects] that
Continue Reading